5:11 PM · 6 March 2025

Hims & Hers drops after court ruling on FDA decision regarding Zepbound📉

Hims & Hers (HIMS.US), a company specializing in selling compounded medications, is experiencing an approximately 8% decline today following a court's rejection of a preliminary injunction request concerning the FDA's decision to remove Zepbound (Eli Lilly's weight-loss drug) from the shortage list.

Under U.S. law, companies can offer copycat versions of brand-name drugs as long as they remain on the shortage list. Therefore, the FDA’s decision has significantly limited the operations of such companies, leading the Outsourcing Facilities Association (OFA) to file a lawsuit against the FDA.

The court’s decision to deny OFA’s request for a preliminary injunction, which would have allowed companies to continue producing lower-cost drug alternatives, is a negative signal for the sector. This is reflected in Hims & Hers' stock price, which has dropped to its lowest level since early February 2025.

The FDA’s decision already led to an 11% decline in Hims & Hers’ stock in December. Today, its shares are down nearly 8%.Source: xStation


 

3 September 2026, 4:03 PM

US Open: Dovish Waller supports the stock market (03.09.2026)

3 September 2026, 11:00 AM

Broadcom Delivers Record Results. The Market Is Already Looking Much Further Ahead

2 September 2026, 6:07 PM

Nasdaq awaits Broadcom earnings. Can the company repeat Nvidia’s success?

2 September 2026, 3:19 PM

US Open: Falling oil prices calm Wall Street 🗽 Dell and GitLab rise, Palo Alto falls

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits